She describes how antibody-drug conjugates have improved over recent years and lists some of her favorite targets and indications that ADCs are going after.
Brought to you by:
Also look for unique social pages for BiotechTV U.
#1. Pfizer’s CEO on Q2 earnings.
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square
